Abstract
The development of O-phosphotyrosine (pTyr) analogues is reviewed, along with their application in peptidomimetic ligands to proteins implicated in disease-states arising from dysfunctional intracellular signal transduction pathways. Salient features of chemical syntheses are critiqued, including those of established mimetics such as 4-(phosphonomethyl)phenylalanine (Pmp), 4- (phosphono)phenylalanine (Ppp) and 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp), their respective (α-methyl)phenylalanine analogues and “preorganised” side-chain cyclised pTyr mimetics. Syntheses of 4-(phosphinomethyl)phenylalanines are also described, as are “bone-directing” residues such as 4-(diphosphonomethyl)phenylalanine (dpmF), 3,4-(diphosphono)phenylalanine and 4- carboxymethyloxy-3-(phosphono)phenylalanine (CPP), capable of eliciting additional interactions with pTyr-binding subsites of specified proteins. The utility of [(4-phosphonomethyl)phenyl]propenoic acid in current developments is also discussed as a route to a range of α- and β-substituted pTyr mimetics, and to pTyr mimetics bearing the requisite β-vinyl functionality to facilitate macrocyclisation via olefin metathesis - of interest in the development of structures exhibiting global conformational constraint. Finally, developments in prodrug presentation of pTyr mimetics are also discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
